All News

Article

Colchicine Ineffective in Long COVID

Jack Cush, MD Oct 21, 2025

Management of long COVID has been perplexing with symptoms having functional and possibly inflammatory origins. Colchicine has been studied in long COVID and failed to improve functional capacity, respiratory function, or inflammatory markers.

Article

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease

Jack Cush, MD Oct 21, 2025

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors have benefits beyond glycemic control, including cardioprotective and nephroprotective effects, with modest weight loss.

Article

FDA Approves Obinutuzumab for Active Lupus Nephritis

Jack Cush, MD Oct 20, 2025

The FDA has approved obinutuzumab (Gazyva) for the treatment of lupus nephritis. This is good news for the more than 1.7 million people worldwide with lupus nephritis.

Meniscal tears - Systematic review of 46 studies - Incidence of 66 per 100,000 - Annual cost of 5 billion to US healthcare - Trend to preserve the meniscus, do less removal, more preservation - Biologic Rx (platelet-rich plasma & stem cell Rx) inconclusive results https://t.co/IPyRFad9GX

Saphnelo (anifrolumab) has been recommended for approval in EU by CHMP for systemic lupus erythematosus (on top of standard therapy) as a once-weekly pre-filled pen. Recommendation based on TULIP-SC Phase III trial. https://t.co/VRUycfLRtf https://t.co/O7cQfkb8BU

Positive CHMP opinion for subcutaneous Saphnelo

12 yr study of 115 Systemic Sclerosis pts shows Finger-to-palm distance (tip 4th finger to distal palmar crease) may be a useful tool for predicting the progression of skin thickening and the development of digital ulcers in the early stages of severe SSc https://t.co/brCEz5Fqac https://t.co/tiVBdfH39q

Predictors of clinical features in early‐onset severe systemic sclerosis: An an…

UK National Joint Registry study of 1.5 million TKR and THA (2010 to 2022); trends show median Length of hosp stay (LOS) decreased from 4.3d to 2.75 d for THR; & from 4.35d to 2.9d for TKR; & from 3.2d to 1.9d for UKR (unilat. knee replacement). Longer LOS with comorbidity, https://t.co/DNBZTPFRsl

Phase 3b/4 head-to-head SELECT-SWITCH study tested Humira vs Rinvoq in 492 RA MTX pts failing a TNFi then Rx w/ ADA vs UPA x12 wks. UPA > ADA w/ DAS28-CRP < 3.2 (43% vs 22%; p<0.001) and also for DAS28-CRP < 2.6 (28% vs 14%). No new safety signals seen.https://t.co/EAJ9GglMjv https://t.co/uHTsdTPpWP

RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for…

Study from Czech ATTRA registry of 8,543 RA pts 641 (7.5%) met criteria for D2T-RA & 1,825 achieved remission (21%). D2T-RA predicted by machine learning models (accuracy 0.606–0.747, AUC 0.656–0.832). Predictors included CDAI, DAS28-ESR, TJC, HAQ, CRP, steroids https://t.co/PqgKzKhM6h

30% of RA pts have non-alcoholic fatty liver disease (NAFLD). In 170 pts on MTX or biologics (TNFi, IL-6i)- NAFLD was found in 36%. MTX & biologics were not linked to NAFLD or fibrosis -- BUT was signif assoc w/ metabolic syndr, BMI, Waist, ALT, and AST (all p < .001) https://t.co/MpkxjHEbxK

Bad Actor Cofactor (10.17.2025) Dr. Jack Cush reviews the news and journal reports, discusses pediatric reports, pregnancy data, diet and nutrition and more https://t.co/zDDLwwRSy9 https://t.co/2S8jPOY0Be

Bad Actor Cofactor (10.17.2025) | RheumNow

Telitacicept Effective in Systemic Lupus Erythematosus The NEJM has published a report from van Vollenhoven et al showing a new dual B cell inhibitor, telitacicept, to be effective when given to active systemic lupus erythematosus (SLE) patients; but this comes with a few https://t.co/lwq8ZUMTQ8

SAIL-RA: Finding ILD in Early RA Cohort study of early rheumatoid arthritis (RA) patients finds that interstitial lung disease (ILD) begins early in the course of RA, with certain factors enhancing this risk. https://t.co/nI0YuYd3YS https://t.co/YR3Gg1kr59

SAIL-RA: Finding ILD in Early RA | RheumNow

FDA has approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy. https://t.co/0eGwGnSDYf https://t.co/Z6w2iP4u3e

FDA Approves Third-Ever Drug for Lupus Nephritis

Retrospective study of 423 seropositiv RA pts (SPRA) finds 21% with baseline ILD; over 10 yrs 31% had ILD. High monocyte counts signif higher in RA-ILD; whereas RF, CCP did not predict. Age & ILD predicted mortality - not monocytes, RF or CCP https://t.co/8H4wqZI3WQ https://t.co/dK9iHwj3cz

https://buff.ly/tV51bFp

Interleukin-18 (IL-18) regulates appetite, body weight & glucose homeostasis. IL-18 deficiency may lead to obesity, but chronic IL-18 signalling promotes liver fibrosis. IL-18 is Elevated in obesity and diabetes mellitus https://t.co/Xylvexqvtg https://t.co/sRutSCoLf9

Interleukin-18 in obesity and obesity-related metabolic diseases

Study of biopsy proven lupus nephritis pts (1970-2024) - a total of 324 LN pts followed for median 9.9 yrs -- 30 (9.3%) developed Venous Thromboembolic event (VTE); time from LN to 1st VTE 4.4 yrs. Predictors were SLEDAI-2K score (HR= 1.05) and proteinuria level (HR 1.26)

From the plenary to posters, RheumNow is your companion for ACR Convergence 2025. Expect: • KOL videos • Clinical trial highlights • Daily faculty recaps • Live streaming #ACR25 #Rheumatology #ClinicalTrials https://t.co/zZAwYINmC2

“Never in the field of human conflict was so much owed by so many to so few.” – Winston Churchill https://t.co/ZAcYBpOmjy

Review of IL-1 family cytokines in inflammation and immunity - including, IL-1, IL-18, IL-33, IL-36, IL-37, IL-38, IL-1Ra, etc. Full read -- Good Reference!! https://t.co/m2CwDydnB0 https://t.co/h90bdzv3y7

IL-1 family cytokines in inflammation and immunity

Topics

All News

Colchicine Ineffective in Long COVID

SGLT-2 inhibitors and the prevention of autoimmune rheumatic disease

FDA Approves Obinutuzumab for Active Lupus Nephritis

Do you get our email newsletter?